Optical Q is a cutting edge in vitro diagnostics (IVD) fluorescence immunoassay (FIA) analyzer that accurately measures the concentration of analytes contained in blood, serum, plasma, and other samples. Results are generated within a prompt 15 minute time frame with CVs ranging from 5%, 10%.
Optical Q features 25 parameters, reagents as seen below:
Inflammation: CRP, PCT
Tumor: AFP, CEA, PSA
Hormone: Beta-hCG, LH, FSH, PRL, Cortisol, Testosterone, Progesterone
Thyroid: TSH, Total T3, Free T3, Total T4, Free T4
Cardiac: Myoglobin, CK MB, D Dimer, NT proBNP
COVID 19: Neutralizing antibody (nAb)
1) Approved by CE (IVD)
2) Rapid and quantitative immunoassay
3) High performance of CV 10%
4) Assay time of 3, 15 minutes
5) 25 Tests, box
In contrast to standard FIA analyzers that use gold nano-particles, Optical Q utilizes advanced fluorescence chemistry and incorporates world class lens technology to more accurately quantify the concentration or severity of each analyte. In addition, Optical Q features a wide variety of diagnostic markers many of which are developed in house that covers health categories including but not limited to inflammation, infection, diabetes, vitamin D deficiency, thyroids, and more. Our capacity to develop our device and antibodies in-house enables optimized performance against competitors, continued expansion of our test menu, and modification of tests based on client needs.
From private physician offices to larger hospital laboratories and emergency departments, Optical Q high performance, objectivity, and quality control make Optical Q the perfect solution for those looking to improve their rapid testing algorithm.
Optical Q is truly a rapid one-stop diagnostic solution.
OptiBio Co., Ltd. is a South Korean in-vitro diagnostics (IVD) company focused in researching, developing, and
manufacturing cutting edge fluorescence immunoassay (FIA) solutions to enhance and progress quality healthcare access globally. In 2020, OptiBio was selected by a research fund sponsored by the Bill Melinda Gates foundation for its unique and dedicated approach to immunoassay. OptiBio's fundamental approach of integrating in-house capabilities allows OptiBio to constantly improve its product performance, customize its solutions based on client feedback, develop new test parameters, and respond to changing market needs. OptiBio will continue to create, improve, and innovate world class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.